CALQUENCE ® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial Read more
Biden largely spent his political capital, the risk is now to the downside: BCA By Investing.com Read more